Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vivos Therapeutics, Inc. - Common Stock (NQ: VVOS )

2.640 -0.070 (-2.58%)
Streaming Delayed Price Updated: 12:52 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,652
Open 2.640
Bid (Size) 2.610 (1)
Ask (Size) 2.660 (2)
Prev. Close 2.710
Today's Range 2.570 - 2.660
52wk Range 1.910 - 6.280
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For March 31, 2025
Via Benzinga
Earnings Outlook For Vivos Therapeutics
Via Benzinga

Performance

YTD
-37.88%
-37.88%
1 Month
-24.36%
-24.36%
3 Month
-43.95%
-43.95%
6 Month
-1.12%
-1.12%
1 Year
+2.72%
+2.72%

More News

Read More
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Via Benzinga
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind”
Via TheNewswire.com
Exposures Product Safety
Why Vision Marine Technologies Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical Devices
Via Investor Brand Network
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
Via Benzinga
Exposures Fossil Fuels
Earnings Scheduled For November 14, 2024
Via Benzinga
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Via Investor Brand Network
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000
Via Benzinga
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Via Benzinga
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update
Via Investor Brand Network
VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Alliance, Private Equity Investment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2024 Financial Report, Operational Update
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
VVOS Stock Earnings: Vivos Therapeutics Reported Results for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2024 Results, Conference Call
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.